SLC5A2 and Stroke: This apparentcontradiction may arise from fundamental differences, as our MR analysis servesas a proxy for lifelong SGLT2 inhibition through SLC5A2 expression,whereas clinical trials evaluate the effects of shorter-term interventions.Therefore, further studies are required to elucidate these findings and clarifythe therapeutic potential of SGLT2 inhibitors in stroke prevention and treatment.